Aceragen Acquires Arrevus to Expand Late-Stage Rare Disease Pipeline
October 28, 2021
Aceragen, Inc. acquired clinical-stage biopharmaceutical company Arrevus, Inc., adding Arrevus' lead oral anti-infective candidate ARV-1801 (renamed ACG-721) and several preclinical programs to Aceragen's rare-disease pipeline. The deal brings additional clinical and regulatory capabilities to Aceragen and is expected to be accretive as the company advances registrational and Phase 2/3 studies in cystic fibrosis and other orphan indications.
- Buyers
- Aceragen, Inc.
- Targets
- Arrevus, Inc.
- Industry
- Biotechnology
- Location
- North Carolina, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
argenx to Acquire Forte Biosciences, Inc.
July 27, 2026
Healthcare Services
argenx entered into a definitive agreement to acquire Forte Biosciences, Inc. for $77 per share in cash, valuing the deal at approximately $2.2 billion. The transaction will be implemented via a tender offer followed by a merger, and is expected to close in Q3 2026 subject to customary closing conditions.
-
Tarsus Pharmaceuticals Acquires iRenix Medical to Advance IRX-101 for Retina Care
July 9, 2026
Biotechnology
Tarsus Pharmaceuticals announced it has acquired iRenix Medical, adding late-stage investigational ocular antiseptic IRX-101 to its eye care pipeline. Under the agreement, Tarsus will pay about $75 million upfront (cash and stock) and make additional regulatory and commercial milestone payments up to $490 million.
-
Biogen Acquires Apellis Pharmaceuticals
March 31, 2026
Healthcare Services
Biogen entered into a definitive agreement to acquire Apellis Pharmaceuticals in a ~$5.6 billion cash deal ($41 per share) that also includes contingent value rights (CVRs) tied to SYFOVRE sales performance. The transaction closed in May 2026 and made Apellis a wholly owned subsidiary of Biogen, adding commercial products EMPAVELI and SYFOVRE to Biogen’s immunology/rare disease portfolio and strengthening its expansion into nephrology.
-
Novartis Acquires Regulus Therapeutics
June 25, 2025
Biotechnology
Novartis has completed the acquisition of Regulus Therapeutics, making Regulus an indirect wholly owned subsidiary following a tender offer and merger. The deal secures Regulus' investigational oligonucleotide therapy farabursen for ADPKD and strengthens Novartis' renal disease pipeline.
-
Zevra Therapeutics Acquires Acer Therapeutics
November 20, 2023
Pharmaceuticals
Zevra Therapeutics completed the acquisition of Acer Therapeutics in a stock-and-contingent-value-rights transaction, bringing the FDA-approved product OLPRUVA and clinical-stage candidate EDSIVO into Zevra's portfolio and transitioning Zevra to a commercial-stage rare disease company. The deal included Zevra's purchase of Acer's senior secured debt and issuance of approximately 2.96 million shares plus CVRs (up to $76 million), and was followed by a registered direct offering to a healthcare-focused investment fund.
-
Idera Pharmaceuticals Acquires Aceragen
September 28, 2022
Biotechnology
Idera Pharmaceuticals completed an all-stock acquisition of Aceragen, a privately held biotech focused on rare pulmonary and rheumatic diseases, adding Aceragen's lead programs ACG-701 and ACG-801 to Idera's pipeline. The transaction was structured as a stock-for-stock exchange, includes management appointments from Aceragen, and is expected to provide pro forma cash runway into Q3 2023 while advancing Aceragen's clinical milestones.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.